Deutsche Bank Maintained IQE PLC (LON:IQE) As Hold; Has PT Of GBX 70.00; Chemocentryx Has 0.93 Sentiment

ChemoCentryx, Inc. (NASDAQ:CCXI) Logo

London: In an analyst note sent to investors and clients on 22 March, Deutsche Bank maintained their Hold rating on shares of IQE PLC (LON:IQE). They currently have a GBX 70.00 TP on the company. Deutsche Bank’s target means a potential downside of -24.12% from the company’s last close price.

Chemocentryx Inc (CCXI) investors sentiment decreased to 0.93 in Q4 2018. It’s down -0.05, from 0.98 in 2018Q3. The ratio has dropped, as 42 hedge funds opened new or increased holdings, while 45 trimmed and sold positions in Chemocentryx Inc. The hedge funds in our database now possess: 27.13 million shares, up from 26.80 million shares in 2018Q3. Also, the number of hedge funds holding Chemocentryx Inc in top ten holdings was flat from 1 to 1 for the same number . Sold All: 7 Reduced: 38 Increased: 24 New Position: 18.

Another recent and important IQE plc (LON:IQE) news was published by Fool.Co.Uk which published an article titled: “This dynamic small-cap is thrashing the IQE share price – Motley Fool UK” on September 10, 2018.

IQE plc develops, manufactures, and sells advanced semiconductor materials worldwide. The company has market cap of 557.83 million GBP. The firm operates through Wireless, Photonics, Infra Red, and CMOS++ divisions. It has a 55.23 P/E ratio. It makes compound semiconductor wafers or epiwafers using epitaxy process; and offers various products, including HBTs, pHEMTs, BiFETs/BiHEMTs, HFETs, LMHEMTs, LNHEMTs, and MESFETs for use in wireless devices, such as mobile phones, smartphones, mobile networks, Wi-Fi, smart metering, satellite navigation, and a plethora of connected devices.

The stock decreased 1.10% or GBX 0.8 during the last trading session, reaching GBX 71.8. About 661,814 shares traded. IQE plc (LON:IQE) has 0.00% since March 22, 2018 and is . It has underperformed by 4.37% the S&P500.

Among 3 analysts covering IQE PLC (LON:IQE), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. IQE PLC has GBX 190 highest and GBX 70 lowest target. GBX 102’s average target is 42.06% above currents GBX 71.8 stock price. IQE PLC had 16 analyst reports since October 1, 2018 according to SRatingsIntel. The stock of IQE plc (LON:IQE) earned “Buy” rating by Peel Hunt on Thursday, February 7. The stock of IQE plc (LON:IQE) earned “Hold” rating by Deutsche Bank on Friday, March 22. The firm has “Buy” rating by Peel Hunt given on Monday, February 4. On Tuesday, November 13 the stock rating was maintained by Peel Hunt with “Buy”. Peel Hunt maintained the stock with “Buy” rating in Monday, October 15 report. Deutsche Bank maintained it with “Hold” rating and GBX 80 target in Wednesday, November 14 report. The firm earned “Overweight” rating on Friday, November 16 by Barclays Capital. Peel Hunt maintained the shares of IQE in report on Friday, November 2 with “Buy” rating. Deutsche Bank maintained the shares of IQE in report on Tuesday, October 2 with “Hold” rating. The firm has “Buy” rating by Peel Hunt given on Friday, November 30.

Bvf Inc Il holds 9.54% of its portfolio in ChemoCentryx, Inc. for 6.69 million shares. P.A.W. Capital Corp owns 50,000 shares or 0.68% of their US portfolio. Moreover, Sio Capital Management Llc has 0.67% invested in the company for 169,257 shares. The Utah-based Wasatch Advisors Inc has invested 0.34% in the stock. Nantahala Capital Management Llc, a Connecticut-based fund reported 623,338 shares.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $551.98 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It currently has negative earnings. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

More important recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Nasdaq.com which released: “ChemoCentryx (CCXI) Reports Q4 Loss, Lags Revenue Estimates – Nasdaq” on March 11, 2019, also Nasdaq.com published article titled: “ChemoCentryx (CCXI) Looks Good: Stock Adds 5.5% in Session – Nasdaq”, Nasdaq.com published: “After-Hours Earnings Report for March 11, 2019 : ADT, COUP, SFIX, DRNA, AVD, PETQ, CCXI, LXFR, MG, OXFD, FRTA, KALA – Nasdaq” on March 11, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) was released by: Globenewswire.com and their article: “New Research: Key Drivers of Growth for Ellie Mae, Spotify Technology SA, Bristow Group, Teradata, ChemoCentryx, and AgroFresh Solutions — Factors of Influence, Major Initiatives and Sustained Production – GlobeNewswire” with publication date: February 26, 2019.

The stock decreased 4.72% or $0.52 during the last trading session, reaching $10.5. About 149,134 shares traded. ChemoCentryx, Inc. (CCXI) has risen 12.22% since March 22, 2018 and is uptrending. It has outperformed by 7.85% the S&P500. Some Historical CCXI News: 20/04/2018 – DJ Chemocentryx Inc, Inst Holders, 1Q 2018 (CCXI); 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 09/03/2018 ChemoCentryx 4Q EPS 80c; 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 09/05/2018 – CHEMOCENTRYX INC – QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19

Since January 1, 0001, it had 0 insider buys, and 8 selling transactions for $87.64 million activity.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *